Combining the past and present to advance immuno-radiotherapy of cancer

References

• Obituary: EH, Grubbe MD, FACP. Br Med J. 1960; 2:609
   Google Scholar
• Baird BJ, Sung CK, Beadle BM, Divi V. Treatment of early-stage laryngeal cancer: a comparison of treatment options. Oral Oncol. 2018; 87:8–16. doi:10.1016/j.oraloncology.2018.09.012.
   PubMed Web of Science ®Google Scholar
• Kamran SC, D’Amico AV. Radiation therapy for prostate cancer. Hematol Oncol Clin North Am. 2020;34(1):45–69.
   PubMed Web of Science ®Google Scholar
• Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017;198(3):552–559. doi:10.1016/j.juro.2017.04.086.
   PubMed Web of Science ®Google Scholar
• Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. Cancer. 2018;124(4):667–678. doi:10.1002/cncr.31196.
   PubMed Web of Science ®Google Scholar
• Brown S, Banfill K, Aznar MC, et al. The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol. 2019;92(1104):20190524.
   PubMed Web of Science ®Google Scholar
• Alterio D, Marvaso G, Ferrari A, et al. Modern radiotherapy for head and neck cancer. Semin Oncol. 2019;46(3):233–245.
   PubMed Web of Science ®Google Scholar
• Vordermark D. Radiotherapy of cervical cancer. Oncol Res Treat. 2016;39(9):516–520. doi:10.1159/000448902.
   PubMed Web of Science ®Google Scholar
• Willers H, Allen A, Grosshans D, et al. Toward A variable RBE for proton beam therapy. Radiother Oncol. 2018;128(1):68–75. doi:10.1016/j.radonc.2018.05.019.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Mitrakas AG, Giatromanolaki A. Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. Br J Cancer. 2016;114(5):485–496. doi:10.1038/bjc.2016.19.
   PubMed Web of Science ®Google Scholar
• Milanovic M, Fan DNY, Belenki D, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553(7686):96–100. doi:10.1038/nature25167.
   PubMed Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–2527.
   PubMed Web of Science ®Google Scholar
• Bashford EF, Murray JA, Cramer W. The natural and induced resistance of mice to the growth of cancer. Proc R Soc Lond. B. 1907; 79:164–187.
   Google Scholar
• Giatromanolaki A, Sivridis E, Koukourakis MI. The pathology of tumor stromatogenesis. Cancer Biol Ther. 2007;6(5):639–645.
   PubMed Web of Science ®Google Scholar
• Mikulska ZB, Smith C, Alexander P. Evidence for an immunological reaction of the host directed against its own actively growing primary tumor. J Natl Cancer Inst. 1966;36(1):29–35.
   PubMedGoogle Scholar
• Berczi I, Strausbauch P, Sehon AH. Rejection of tumor cells in vitro. Science. 1973;180(4092):1289–1291. doi:10.1126/science.180.4092.1289.
   PubMed Web of Science ®Google Scholar
• Jurin M, Suit HD. In vivo and in vitro studies of the influence of the immune status of C3Hf-Bu mice on the effectiveness of local irradiation of a methylcholanthrene-induced fibrosarcoma. Cancer Res. 1972;32(10):2201–2211.
   PubMed Web of Science ®Google Scholar
• Shiku H, Kisielow P, Bean MA, et al. Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med. 1975;141(1):227–241. doi:10.1084/jem.141.1.227.
   PubMed Web of Science ®Google Scholar
• Kiessling R, Klein E, Wigzell H. Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution, according to genotype. Eur J Immunol. 1975;5(2):112–117.
   PubMed Web of Science ®Google Scholar
• Ojo E. Positive correlation between the levels of natural killer cells and the in vivo resistance to syngeneic tumor transplants as influenced by various routes of administration of Corynebacterium parvum bacteria. Cell Immunol. 1979;45(1):182–187. doi:10.1016/0008-8749(79)90374-5.
   PubMed Web of Science ®Google Scholar
• Hassan ZM, Rees RC, Potter CW. Corynebacterium parvum stimulation of adherent and non-adherent cytotoxic cells in mice. Br J Cancer. 1981;44(4):532–538. doi:10.1038/bjc.1981.222.
   PubMed Web of Science ®Google Scholar
• Evans R, Alexander P. Mechanism of immunologically specific killing of tumour cells by macrophages. Nature. 1972;236(5343):168–170. doi:10.1038/236168a0.
   PubMed Web of Science ®Google Scholar
• Keller R. Modulation of cell proliferation by macrophages: a possible function apart from cytotoxic tumour rejection. Br J Cancer. 1974;30(5):401–415. doi:10.1038/bjc.1974.214.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Landolfo S, Zawatzky R, Kirchner H. Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, gamma-interferon induction, and cytotoxic response. Invasion Metastasis. 1981;1(3):175–194.
   PubMedGoogle Scholar
• Isaacs A, Lindenmann J. Virus interference. I. The Interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258–267. [Database] doi:10.1098/rspb.1957.0048.
   PubMed Web of Science ®Google Scholar
• Chany C. An inhibiting factor of intracellular multiplication of viruses called Interferon, originating from cancer cells. The phenomenon of viral autoinhibition. C R Hebd Seances Acad Sci. 1960; 250:3903–3905.
   PubMedGoogle Scholar
• Lee SH, Ozere RL, Van Rooyen CE. Interferon production by human leucocytes in vitro. Reduced levels in lymphatic leukemia. Proc Soc Exp Biol Med. 1966;122(1):32–39.
   PubMed Web of Science ®Google Scholar
• Gresser I, Bourali C, Lévy JP, et al. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci U S A. 1969;63(1):51–57. doi:10.1073/pnas.63.1.51.
   PubMed Web of Science ®Google Scholar
• Gresser I, Bourali C. Antitumor effects of interferon preparations in mice. J Natl Cancer Inst. 1970;45(2):365–376.
   PubMedGoogle Scholar
• Gutterman JU, Blumenschein GR, Alexanian R, et al. interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980;93(3):399–406.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Levine JF, Miller RA, et al. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA. 1982;247(12):1718–1722. doi:10.1001/jama.1982.03320370032025.
   PubMed Web of Science ®Google Scholar
• Golub SH, D’Amore P, Rainey M. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity. J Natl Cancer Inst. 1982; 68:711–717.
   PubMedGoogle Scholar
• Mochizuki DY, Watson J, Gillis S. Biochemical separation of interleukin 2. J Immunol Methods. 1980;39(3):185–201.
   PubMed Web of Science ®Google Scholar
• Mills GB, Paetkau V. Generation of cytotoxic lymphocytes to a syngeneic tumor by using co-stimulator (Interleukin 2). J Immunol. 1980;125(5):1897–1903.
   PubMed Web of Science ®Google Scholar
• Thayer A. Interleukin-2 wins FDA market clearance. Chem Eng News Archive. 1992;70(19):5. doi:10.1021/cen-v070n019.p005.
   Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Santinami M, et al. EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet. 2008;372(9633):117–126. ; doi:10.1016/S0140-6736(08)61033-8.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• MacDowell EC, Taylor MJ, Potter JS. The dependence of protection against a transplantable mouse leukemia upon the genetic constitution of the immunizing tissue. Proc Natl Acad Sci U S A. 1935;21(8):507–508. doi:10.1073/pnas.21.8.507.
   PubMedGoogle Scholar
• Sturm E. Induced resistance to a transplantable lymphatic leukemia in rats. Cancer Res. 1941; 1:627–628.
   Google Scholar
• Murphy JB, Sturm A. The effect of adrenal grafting on transplanted lymphatic leukemia. Cancer Res. 1950;10(3):191–193.
   PubMed Web of Science ®Google Scholar
• Sturm E, Murphy JB. The effect of adrenalectomy on the susceptibility of rats to a transplantable leukemia. Cancer Res. 1944; 4:384–388.
   Google Scholar
• Symes MO, Mitchell JP, Eckert H, et al. Transfer of adoptive immunity by intra-arterial injection of tumor-immune pig lymph node cells: treatment of recurrent urinary bladder carcinoma after radical radiotherapy. Urology. 1978;12(4):398–401. doi:10.1016/0090-4295(78)90288-1.
   PubMedGoogle Scholar
• Clowes GHA, Baeslack FW. Further evidence of immunity against cancer in mice after spontaneous recovery. Med News. 1905; 87:968–971.
   Google Scholar
• Besredka A, Gross L. De l’immunisation contre le sarcome de la souris par vole intracutane. Ann. Inst. Pasteur. 1935; 55:491–500.
   Google Scholar
• Gross L. Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line. Cancer Res. 1943; 3:326–333.
   Google Scholar
• Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953;13(12):835–837.
   PubMed Web of Science ®Google Scholar
• Lewis MR, Aptekman MB. Atrophy of tumors caused by strangulation and accompanied by development of tumor immunity in rats. Cancer. 1952; 6:411–413.
   Google Scholar
• Stjernswärd J, Vánky F, Klein E. Lymphocyte stimulation by autochthonous human solid tumours. Br J Cancer Suppl. 1973; 1:72–76.
   PubMedGoogle Scholar
• Avatkins E, Ogata Y, Anderson LL. Activation of Host lymphocytes cultured with cancer cells, treated with neuramidase. Nature (New Biol.). 1971; 231:83.
   PubMed Web of Science ®Google Scholar
• Vánky F, Stjernswärd J, Klein G, Nilsonne U. Serum-mediated Inhibition of lymphocyte stimulation by autochthonous human tumors. J Natl Cancer Inst. 1971;47(1):95–103.
   PubMedGoogle Scholar
• Simmons RL, Rios A, Lundgren G, Ray PK. Immunotherapy of methylcholanthrene fibrosarcoma using neuraminidase. Fed Proc. 1971; 30:246.
   Google Scholar
• Weiss L, Mlavhew E, Ulrieh K. The effect of neuraminidase on the fate of transfused lymphocytes. Lab Invest. 1966; 15:1304.
   PubMed Web of Science ®Google Scholar
• Simmons RL, Rios A, Ray PK. Immunogenicitv and antigenicity of lymphoid cells treated with neoiraminidase. Nature (New Biol.). 1971;231(23):179–181. doi:10.1038/newbio231179a0.
   PubMed Web of Science ®Google Scholar
• Juillard GJ, Boyer PJ, Snow HD. Intralymphatic infusion of autochthonous tumor cells in canine lymphoma. Int J Radiat Oncol Biol Phys. 1976;1(5-6):497–503.
   PubMed Web of Science ®Google Scholar
• Kellock TH, Chambers H, Russ S. An attempt to produce immunity to malignant disease in man. Lancet. 1922;199(5136):217–219. doi:10.1016/S0140-6736(01)25621-9.
   Google Scholar
• Anderson MJ, Kelly F, Wood SE, et al. Evaluation of Leukocyte function six years after tumour autograft in human mammary cancer. Br J Cancer. 1973; 28 (Suppl. I):83.
   Google Scholar
• Anderson JM, Kelly F, Gettinby G, Wood SE. Prolonged survival after immunotherapy (irradiated cancer autografts) or mammary cancers, assessed by a measure of therapeutic deficiency. Cancer. 1977;40(1):30–35. doi:10.1002/1097-0142(197707)40:1<30::AID-CNCR2820400107>3.0.CO;2-S.
   PubMed Web of Science ®Google Scholar
• Laucius JF, Bodurtha AJ, Mastrangelo JM, Bellet RE. A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer. 1977;40(5):2091–2093. doi:10.1002/1097-0142(197711)40:5<2091::AID-CNCR2820400517>3.0.CO;2-H.
   PubMed Web of Science ®Google Scholar
• Hedley DW, McElwain TJ, Currie GA. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence. Br J Cancer. 1978;37(4):491–496. doi:10.1038/bjc.1978.76.
   PubMed Web of Science ®Google Scholar
• Hudson CN, McHardy JE, Curling OM, et al. Active specific immunotherapy for ovarian cancer. Lancet. 1976;2(7991):877–879. doi:10.1016/S0140-6736(76)90539-0.
   PubMed Web of Science ®Google Scholar
• Juillard GJ, Boyer PJ, Yamashiro CH. A phase I study of active specific intra-lymphatic immunotherapy (ASILI). Cancer. 1978;41(6):2215–2225. doi:10.1002/1097-0142(197806)41:6<2215::AID-CNCR2820410622>3.0.CO;2-X.
   PubMed Web of Science ®Google Scholar
• Stack BH, McSwan N, Stirling JM, et al. Cell-mediated immunity in operable bronchial carcinoma: the effect of injecting irradiated autologous tumour cells and BCG. Thorax. 1979;34(1):68–73. doi:10.1136/thx.34.1.68.
   PubMed Web of Science ®Google Scholar
• McCune CS, Patterson WB, Henshaw EC. Active specific immunotherapy with tumor cells and Corynebacterium parvum: a phase I study. Cancer. 1979;43(5):1619–1623. doi:10.1002/1097-0142(197905)43:5<1619::AID-CNCR2820430509>3.0.CO;2-O.
   PubMed Web of Science ®Google Scholar
• McCune CS, Schapira DV, Henshaw EC. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer. 1981;47(8):1984–1987. doi:10.1002/1097-0142(19810415)47:8<1984::AID-CNCR2820470814>3.0.CO;2-J.
   PubMed Web of Science ®Google Scholar
• Souter RG, Gill PG, Gunning AJ, Morris PJ. Failure of specific active immunotherapy in lung cancer. Br J Cancer. 1981;44(4):496–501. doi:10.1038/bjc.1981.217.
   PubMed Web of Science ®Google Scholar
• Wiseman C, Jessup JM, Smith TL, et al. Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy. Cancer. 1982;49(6):1266–1271. doi:10.1002/1097-0142(19820315)49:6<1266::AID-CNCR2820490631>3.0.CO;2-6.
   PubMed Web of Science ®Google Scholar
• Mahaley MS, Jr, Bigner DD, Dudka LF, et al. Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg. 1983;59(2):201–207.
   PubMed Web of Science ®Google Scholar
• Jessup JM, McBride CM, Ames FC, et al. Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine. Cancer Immunol Immunother. 1986; 21:233–239.
   PubMed Web of Science ®Google Scholar
• Gray BN, Walker C, Andrewartha L, et al. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. J Surg Oncol. 1989;40(1):34–37. doi:10.1002/jso.2930400109.
   PubMed Web of Science ®Google Scholar
• Adler A, Gillon G, Lurie H, et al. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod. 1987;6(6):610–624.
   PubMedGoogle Scholar
• Berd D, Mastrangelo MJ. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest. 1988;6(3):337–349. doi:10.3109/07357908809080657.
   PubMed Web of Science ®Google Scholar
• Wiseman CL, Rao VS, Kennedy PS, et al. Clinical responses with active specific intralymphatic immunotherapy for cancer–a phase I-II trial. West J Med. 1989;151(3):283–288.
   PubMedGoogle Scholar
• Berd D, Maguire HC, Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990;8(11):1858–1867. doi:10.1200/JCO.1990.8.11.1858.
   PubMed Web of Science ®Google Scholar
• Schlag P, Manasterski M, Gerneth T, et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother. 1992;35(5):325–330. doi:10.1007/BF01741145.
   PubMed Web of Science ®Google Scholar
• Dillman RO, DeLeon C, Beutel LD, et al. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol. 2001;39(1-2):115–123. doi:10.1016/s1040-8428(01)00110-x.
   PubMed Web of Science ®Google Scholar
• Lotem M, Peretz T, Drize O, et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer. 2002;86(10):1534–1539. doi:10.1038/sj.bjc.6600251.
   PubMed Web of Science ®Google Scholar
• Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Cancer. 1996; 77:2560–2566. doi:10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P.
   PubMed Web of Science ®Google Scholar
• Stack BH, McSwan N, Stirling JM, et al. Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer. Thorax. 1982;37(8):588–593. doi:10.1136/thx.37.8.588.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet. 1999;353(9150):345–350. doi:10.1016/S0140-6736(98)07186-4.
   PubMed Web of Science ®Google Scholar
• Harris JE, Ryan L, Hoover HC, Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: eastern cooperative oncology group study E5283. JCO. 2000;18(1):148–157. doi:10.1200/JCO.2000.18.1.148.
   PubMed Web of Science ®Google Scholar
• Bekesi JG, Roboz JP, Holland JF. Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia. Ann N Y Acad Sci. 1976;277(00):313–331. doi:10.1111/j.1749-6632.1976.tb41710.x.
   PubMedGoogle Scholar
• Powles R, Toy JL. The effect of immunotherapy on survival of patients with acute myelogenous leukaemia after relapse. Haematologia (Budap). 1976;10(1):5–9.
   PubMedGoogle Scholar
• Ohno R, Nakamura H, Kodera Y, et al. Randomized controlled study of chemoimmunotherapy of acute myelogenous leukemia (AML) in adults with Nocardia rubra cell-wall skeleton and irradiated allogeneic AML cells. Cancer. 1986;57(8):1483–1488. doi:10.1002/1097-0142(19860415)57:8<1483::AID-CNCR2820570808>3.0.CO;2-7.
   PubMed Web of Science ®Google Scholar
• Hayat M, Jehn U, Willemze R, et al. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A leukemia-lymphoma group trial of the EORTC. Cancer. 1986;58(3):617–623. doi:10.1002/1097-0142(19860801)58:3<617::AID-CNCR2820580304>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Urbanitz D, Büchner T, Pielken H, et al. Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial. Haematol Blood Transfus. 1987; 30:64–68. doi:10.1007/978-3-642-71213-5_11.
   PubMedGoogle Scholar
• Kirchner HH, Atzpodien APJ. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol. 1995; 13:171–173.
   PubMed Web of Science ®Google Scholar
• Pomer S, Schirrmacher V, Thiele R, et al. Tumor response and 4 year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b). Int J Oncol. 1995; 6:947–954.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Depriest C, McClure SE. High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. Cancer Biother Radiopharm. 2014;29(2):53–57. doi:10.1089/cbr.2013.1565.
   PubMed Web of Science ®Google Scholar
• Mordoh J, Pampena MB, Aris M, et al. Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus bacillus Calmette-Guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose interferon alpha 2B in stages IIB, IIC, and III cutaneous melanoma patients: a single institution. Front Immunol. 2017; 8:625.
   PubMed Web of Science ®Google Scholar
• Kusumoto M, Umeda S, Ikubo A, et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother. 2001;50(7):373–381. doi:10.1007/s002620100213.
   PubMed Web of Science ®Google Scholar
• Tani K, Azuma M, Nakazaki Y, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther. 2004;10(4):799–816.
   PubMed Web of Science ®Google Scholar
• Buchner A, Pohla H, Willimsky G, et al. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum Gene Ther. 2010;21(3):285–297.
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253(2):328–335.
   PubMed Web of Science ®Google Scholar
• Kugler A, Seseke F, Thelen P, et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br J Urol. 1998;82(4):487–493.
   PubMedGoogle Scholar
• Krause SW, Neumann C, Soruri A, et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother. 2002;25(5):421–428.
   PubMed Web of Science ®Google Scholar
• Homma S, Kikuchi T, Ishiji N, et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest. 2005;35(4):279–286.
   PubMed Web of Science ®Google Scholar
• Wei Y, Sticca RP, Holmes LM, et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol. 2006;28(3):585–593.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A. Tumor microenvironment, immune response and post-radiotherapy tumor clearance. Clin Transl Oncol. 2020;22(12):2196–2205.
   PubMed Web of Science ®Google Scholar
• Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogs that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogs in cancer immunotherapy. Cancer Res. 1993;53(11):2597–2602.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A. Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy. Crit Rev Oncol Hematol. 2021; 159(103226):103226.
   PubMedGoogle Scholar
• Interferon approved for marketing by FDA. Chem Eng News. 1986; 64:7.
   Web of Science ®Google Scholar
• Crowther D, Scarffe JH, Howell A, et al. Growth factor-assisted chemotherapy–the Manchester experience. Ciba Found Symp. 1990; 148:201–210.
   PubMedGoogle Scholar
• Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med. 1988;167(2):700–705.
   PubMed Web of Science ®Google Scholar
• Borden EC. Interferons α and β in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019;18(3):219–234.
   PubMed Web of Science ®Google Scholar
• Torrisi J, Berg C, Harter K, et al. Phase I combined modality clinical trial of alpha-2-interferon and radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12(8):1453–1456.
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Jääskeläinen J, Kallio M, et al. Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer. 1994;70(1):138–141. doi:10.1038/bjc.1994.263.
   PubMed Web of Science ®Google Scholar
• Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer. 2001;92(2):420–433. doi:10.1002/1097-0142(20010715)92:2<420::AID-CNCR1338>3.0.CO;2-3.
   PubMed Web of Science ®Google Scholar
• Tummarello D, Mari D, Graziano F, et al. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. Cancer. 1997;80(12):2222–2229. doi:10.1002/(SICI)1097-0142(19971215)80:12<2222::AID-CNCR2>3.0.CO;2-W.
   PubMed Web of Science ®Google Scholar
• van Zandwijk N, Groen HJ, Postmus PE, et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC lung cancer cooperative group. Eur J Cancer. 1997;33(11):1759–1766. doi:10.1016/s0959-8049(97)00174-3.
   PubMed Web of Science ®Google Scholar
• Mantz CA, Vokes EE, Stenson K, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001;7(2):140–148.
   PubMed Web of Science ®Google Scholar
• Gennatas C, Dardoufas C, Mouratidou D, et al. Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-alpha2b. Ann Oncol. 2003;14(3):378–382. doi:10.1093/annonc/mdg105.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus Interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30(33):4077–4083.
   PubMed Web of Science ®Google Scholar
• Basu P, Jenson AB, Majhi T, et al. Phase 2 randomized controlled trial of radiation therapy plus concurrent interferon-alpha and retinoic acid versus cisplatin for stage III cervical carcinoma. Int J Radiat Oncol Biol Phys. 2016;94(1):102–110.
   PubMed Web of Science ®Google Scholar
• Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 1997;80(1):42–49. doi:10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H.
   PubMed Web of Science ®Google Scholar
• De Stefani A, Forni G, Ragona R, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer. 2002;95(1):90–97. doi:10.1002/cncr.10654.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Fisher RI, Leblanc M, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood. 2008;111(8):4048–4054. ). doi:10.1182/blood-2007-09-111708.
   PubMed Web of Science ®Google Scholar
• Curti B, Crittenden M, Seung SK, et al. Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma. J Immunother Cancer. 2020;8(1):e000773.
   PubMed Web of Science ®Google Scholar
• Bunn PA, Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. JCO. 1995;13(7):1632–1641. doi:10.1200/JCO.1995.13.7.1632.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–852. doi:10.1016/j.immuni.2014.10.019.
   PubMed Web of Science ®Google Scholar
• Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65–85.
   PubMed Web of Science ®Google Scholar
• Dagoglu N, Karaman S, Caglar HB, Oral EN. Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases. Cureus. 2019;11(2):e4103.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014; 3:e28780. doi:10.4161/onci.28780.
   PubMed Web of Science ®Google Scholar
• Koukourakis IM, Giakzidis AG, Kouroupi M, et al. Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy. BJR Case Rep. 2021; 6:20200170.
   Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. ; doi:10.1056/NEJMoa1709937.
   PubMed Web of Science ®Google Scholar
• Wu YL, Tsuboi M, He J, et al. Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(18):1711–1723. doi:10.1056/NEJMoa2027071.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Drake CG, Beer TM, et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase iii trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol. 2020;78(6):822–830. ;. doi:10.1016/j.eururo.2020.07.032.
   PubMed Web of Science ®Google Scholar
• Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of Pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276–1282. doi:10.1001/jamaoncol.2019.1478.
   PubMed Web of Science ®Google Scholar
• McBride S, Sherman E, Tsai CJ, et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2021;39(1):30–37.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Ferris RL, Psyrri A, et al. 910O-Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally 1280 advanced squamous cell carcinoma of the head and neck (LA SCCHN). Ann Oncol. 2020; 31:S658. doi:10.1016/j.annonc.2020.08.1025.
   Web of Science ®Google Scholar
• Bourhis J, Sire C, Tao Y, et al. LBA38 Pembrolizumab versus cetuximab, concomitant with 1283 radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 ‘PembroRad’ randomized trial. Ann Oncol. 2020; 31:S1168. doi:10.1016/j.annonc.2020.08.2268.
   Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis IM, Chatzipantelis P, et al. Rectal cancer induces a regulatory lymphocytic phenotype in the tumor-draining lymph nodes to promote cancer cell installation. Immunol Res. 2020;68(6):363–372.
   PubMed Web of Science ®Google Scholar
• Minn I, Rowe SP, Pomper MG. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. Lancet Oncol. 2019;20(8):e443-51–e451. doi:10.1016/S1470-2045(19)30461-9.
   Web of Science ®Google Scholar